GlaxoSmithKline agrees to a $2.2B settlement for 80,000 Zantac lawsuits over cancer claims.

GlaxoSmithKline (GSK) has agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits in the U.S. related to its heartburn drug Zantac, which plaintiffs claim caused cancer. This settlement addresses 93% of pending cases and does not involve an admission of liability. GSK asserts there is no reliable evidence linking Zantac to cancer risk. The company anticipates completing the settlement by mid-2025.

October 09, 2024
53 Articles